These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 1970381)

  • 1. Modern vaccines. Human immunodeficiency virus and AIDS: challenges and progress.
    Schild GC; Minor PD
    Lancet; 1990 May; 335(8697):1081-4. PubMed ID: 1970381
    [No Abstract]   [Full Text] [Related]  

  • 2. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for an AIDS vaccine.
    Girard M
    Cancer Detect Prev; 1990; 14(3):411-3. PubMed ID: 2117487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIV and FIV vaccine studies at UC Davis: 1991 update.
    Gardner M; Yamamoto J; Marthas M; Miller C; Jennings M; Rosenthal A; Luciw P; Planelles V; Yilma T; Giavedoni L
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1495-8. PubMed ID: 1334682
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of the development of an AIDS vaccine.
    Lasky LA
    Crit Rev Immunol; 1989; 9(3):153-72. PubMed ID: 2673294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination against SIV infection and disease.
    Gardner MB
    AIDS Res Hum Retroviruses; 1990 Jul; 6(7):835-46. PubMed ID: 2167709
    [No Abstract]   [Full Text] [Related]  

  • 9. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine.
    Igarashi T; Ami Y; Yamamoto H; Shibata R; Kuwata T; Mukai R; Shinohara K; Komatsu T; Adachi A; Hayami M
    J Gen Virol; 1997 May; 78 ( Pt 5)():985-9. PubMed ID: 9152414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AIDS virus can take on many guises.
    Marx JL
    Science; 1988 Aug; 241(4869):1039-40. PubMed ID: 2457946
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunization against HIV. Problems in developing a vaccine].
    Uhl D
    Med Monatsschr Pharm; 1988 Nov; 11(11):376-8. PubMed ID: 3059163
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus.
    Cranage MP; Polyanskaya N; McBride B; Cook N; Ashworth LA; Dennis M; Baskerville A; Greenaway PJ; Corcoran T; Kitchin P
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):13-22. PubMed ID: 8427714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models for HIV infection and AIDS: memorandum from a WHO meeting.
    Bull World Health Organ; 1988; 66(5):561-74. PubMed ID: 2850118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
    J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
    Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
    Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
    Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
    J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.